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generics, in New Zealand and 16 European countries. Methods: Ex-
factory price data as of December 2012 from New Zealand and 16
European countries were compared for a basket of 14 medicines, most
of which were at least partially funded by the state in the 17 countries.
Five medicines had, at least in some countries, generic versions on the
market whose prices were also analyzed. Medicine price data for the
16 European countries were provided by the Pharma Price Information
service. New Zealand medicine prices were retrieved from the New
Zealand Pharmaceutical Schedule. Unit prices converted into euro
were compared at the ex-factory price level. Results: For the 14
medicines surveyed, considerable price differences at the ex-factory
price level were identiﬁed. Within the European countries, prices in
Greece, Portugal, the United Kingdom, and Spain ranked at the loweree front matter Copyright & 2015, International S
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were at the upper end. The results for New Zealand compared with
Europe were variable. New Zealand prices were found in the lowest
quartile for ﬁve medicines and in the highest quartile for seven other
products. Price differences between the originator products and
generic versions ranged from 0% to 90% depending on the medicine
and the country. Conclusions: Medicine prices varied considerably
between European countries and New Zealand as well as among the
European countries. These differences are likely to result from
national pricing and reimbursement policies.
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Access to essential medicines is a fundamental human right [1].
About one third of the world’s population is unable to access
essential medicines. The concept of essential medicines as a
strategy to ensure access is not only intended for low- and
middle-income countries, but it was argued that rich countries
should follow the lead of poor countries and adopt a more
systematic way of controlling the cost of medicines [2]. The price
of a medicine is an important factor in the accessibility and
affordability of medicines. The World Health Organization rec-
ommends that policymakers implement strategies to manage
medicine prices to ensure that medicines are accessible to the
community and the individual [3]. Medicines are considered a
public health commodity; hence, in many countries, medicine
prices, at least for speciﬁc, usually (partially) funded medicines,
are regulated by the government [4]. In the European Union (EU),
common understanding has been reached that pharmaceutical
pricing and reimbursement policies should balance the partially
conﬂicting policy goals of access to medicines, reward forinnovation, and budget control [5] and that member states have
the authority to regulate prices of medicines purchased by, or
reimbursed by, the state [6].
Pharmaceutical pricing policies are thus affected by govern-
ments with regard to public health objectives, such as access to
affordable medicines, and national industry policies, such as
reward for innovation. In response to the pricing framework set
by government authorities, the pharmaceutical industry often
reacts by developing the most appropriate pricing strategies from
its perspective [7]. An example would, for instance, be submis-
sion to the National Institute for Health and Care Excellence. It is
well known that the National Institute for Health and Care
Excellence in the United Kingdom, which operates with an
approximately £30k threshold, receives a large proportion of
submissions with a cost of approximately £29k per incremental
cost-effectiveness ratio.
As a result of both government policies and pharmaceutical
industry strategies, medicines prices differ among countries [8,9].
Differences may occur at different price levels; for instance, a
country might have a comparably low ex-factory price level (i.e.,ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 8 4 – 4 9 2 485the manufacturer price), but might have consistently high “end
prices” (pharmacy retail prices) for the patients due to the adding
of distribution remuneration such as margins and/or value-added
tax rate [10,11].
One of the aims of both European and New Zealand medicines
policies is to ensure that the public has access to affordable
medicines [12]. New Zealand has been successful in containing
pharmaceutical costs, primarily via the policies of the Pharma-
ceutical Management Agency of New Zealand who manages most
of the pharmaceutical expenditures [13,14].
In New Zealand, medicines are classiﬁed as either funded
medicines or nonfunded medicines. Funded medicines are listed
on the Pharmaceutical Schedule and are subsidized by the
government from the pharmaceutical budget [14]. In New Zea-
land, medicines will cost the patient either NZ $5 (around €3) an
item if the medicine is fully funded or both the patient and the
government will pay for the medicine if the medicine is partly
subsidized. For medicines not available on the Pharmaceutical
Schedule (nonfunded medicines), the patient has to pay “out of
pocket” [15].
In European countries, there are different national pricing and
reimbursement policies that apply similar tools but vary in detail
[12,16]. As in New Zealand, medicines used in the outpatient
sector may be funded, at least partially, or not; thus, medicines
are classiﬁed either as nonreimbursable (no public funding) or as
reimbursable, which means that they are eligible for reimburse-
ment. In most European countries, several reimbursable medi-
cines are not fully funded by public payers but instead are
reimbursed to a speciﬁc percentage [17]. In the inpatient sector,
some high-cost medicines are used that are fully funded by the
government, resulting in no cost for the inpatients [18].
In European countries, prices of reimbursable medicines tend
to be regulated at ex-factory or wholesale (i.e., pharmacy pur-
chasing) price level, whereas manufacturers are usually permit-
ted to set the price of nonreimbursable medicines [19]. A key
methodology guiding public authorities in deciding on the med-
icine prices is external price referencing, that is, the practice of
using the price(s) of a medicine in one or several countries to
derive a benchmark or reference price for the purposes of setting
or negotiating the price [20]. This is a frequently used approach,
applied in all EU member states except Denmark, Sweden, and
the United Kingdom, and in Norway and Switzerland [21]. How-
ever, value-based pricing, when the price of a medicine is set
according to the value it generates, is much less common as a
policy: It is in place only in Sweden. The United Kingdom had
planned to introduce it in 2014; however, it has refrained from
doing so now. Nevertheless, nearly in all European countries,
some element of value-based pricing is being used [22]. Whole-
sale and pharmacy remuneration is added, usually for all med-
icines. They usually take the form of ﬁxed mark-ups and
regressive margin schemes, but they might also be organized as
fee-for-service remuneration, which covers the cost of pharmacy
services such as in England, The Netherlands, and Switzerland
[23]. Unlike many other countries in which prices for patients are
increased by several fees, duties, and taxes, the value-added tax
is the only add-on on the pharmacy retail prices net in European
countries, and usually a lower rate is applied on medicines
compared with the standard rate, amounting to around 5% till
20% [24,25].
A number of studies that analyze and compare medicine
prices in European countries have been published. In some
studies, several European countries have been selected whereas
in others a comparison has been done with the United States [8–
10,26–34]. Some price analyses focused on generic medicine
prices compared with the originators [35–38]. To our knowledge,
no comparison between New Zealand prices and prices in other
high-income economies, such as European countries, has beenundertaken. Moreover, it has often been thought that medicines
available on the Pharmaceutical Schedule in New Zealand and
subsidized by the government have very low prices in interna-
tional terms; however, very little empirical evidence is available
to substantiate this claim [39].
Hence, in this study, we compare medicine prices in European
countries with New Zealand prices for a basket of medicines, all
of which are funded in New Zealand and most of which are, at
least partially, funded by the government in the European
countries. This research will allow the assessment of differences
in prices of medicines, including originator and generic medi-
cines, among the countries.Methods
Country Selection
Seventeen countries were selected for the price survey and the
analysis. These were New Zealand and 16 European countries:
Austria, Belgium, Denmark, Germany, Greece, Finland, France,
Italy, Ireland, The Netherlands, Norway, Portugal, Spain, Sweden,
Switzerland, and the United Kingdom. Fourteen of the 16 Euro-
pean countries are members of the EU (Norway and Switzerland
are nonmembers), and they have similar economic situations to
New Zealand even though some countries (Greece, Portugal,
Spain, and Ireland) have been strongly hit by the global ﬁnancial
crisis [23]. All selected European countries apply price regulation
for at least part of the medicines on the market [40]. Three of the
14 European countries (Denmark, Sweden, and the United King-
dom) currently do not use international price comparisons
(external price referencing) in the pricing decisions.Medicine Selection
Selecting the basket of medicines was guided by the following
principles: to have an equal balance of medicines of different
indications, of different price segments (medicines to be known
as high-price medicines and those of high volume but lower
prices), different patent expiry status, and different reimburse-
ment status. Another major selection criterion for the medicines,
and particularly for the pharmaceutical presentation subject to
the analysis, was the actual availability of medicines on the
market in most of the countries.
We drew up a preliminary sample of 43 medicines, applied the
selection criteria, and generated a ﬁnal list of 14 medicines. The
medicines were checked to ensure that for every medicine each
country had available price data for identical or at least com-
parable presentations. Comparable presentations were deﬁned as
medicines with the same pharmaceutical form (e.g., tablets and
vial), the same dosage, and the same or, if not available, the
closest pack size. If price data on generics were available, the
lowest-priced generic version was chosen. In total, for 5 of the 14
medicines, generics versions were available, however, with var-
iations in country coverage. In case the originator medicines were
available under two brands with a different price, the lower
priced brand was selected. If the originator presentation was
available only in a different pack size than the one of the selected
presentation, this pack size was also chosen for the generic
version, if available, to ensure comparability. Table 1 presents
the selected medicines and the actual presentation chosen for
the price comparison and analysis and provides information on
the country coverage and possible limitations. Although high
country coverage (at least 14 of the 17 countries) was ensured for
the selected medicines with regard to the originator, the coverage
of the generics was poor in most of the cases. We still decided to
Table 1 – Basket of 14 medicines analyzed (medicines analyzed and limitations regarding comparability).
Active ingredient Trade name Therapeutic indication Selected presentation Number of
countries
available for
analysis
Comments and limitations related to
availability/comparability
Abacavir sulphate Ziagen HIV infection 60 f/c tablets 300 mg 16 Data for selected presentation available in 16 countries.
Data for IT were available in considerably different
pack size (10 f/c tablets) and were not included.
Adefovir dipivoxil Hepsera Hepatitis B infection 30 tablets 10 mg 16 Data for selected presentation available in 16 countries.
No price data for PT available.
Aripiprazole Abilify Schizophrenia, bipolar
disorder, antipsychotic
28 tablets 10 mg 17 Data for selected presentation available in 14 countries.
Data for NZ (30 f/c tablets) and for NO and SE (14 f/c
tablets) available in different pack size.
Cyclosporin Neoral/
Sandimmune
Immunosuppressant 50 capsules 100 mg 17 Data for selected presentation available in 12 countries.
Data for ES, IT, IE, NL, and UK in different pack size
(30 capsules) available; in IT, IE, and UK, both Neoral
and Sandimmum were available in 30 capsules 100
mg—Neoral was chosen because in NZ only Neoral is
available.
Cyclosporin Generic versions Immunosuppressant 50 capsules 100 mg 7 Data for selected presentation available in 5 countries.
Data for NL and UK in different pack size (30
capsules) available. No price data for 10 countries.
Darunavir
ethanolate
Prezista HIV infection 60 tablets 600 mg 17 Data for selected presentation available in 17 countries.
Escitalopram Lexapro, Cipralex,
Esertia, Entact,
Seroplex,
Sipralexa
Depression, anxiety,
antidepressant
28 f/c tablets 10 mg 16 Data for selected presentation available in 14 countries.
Data for EL and DE in different pack size (20 and 14 f/
c tablets) available; they were included. No price data
for escitalopram O in NZ available (but not
reimbursed; generic version reimbursed and sole
supply). In EL, ES, IT, and SE, 2 O with same price for
identical presentation are available.
Escitalopram Generic versions Depression, anxiety,
antidepressant
28 f/c tablets 10 mg 5 Data for selected presentation available in 3 countries.
Data for EL and FI in different pack size (EL and FI 30
f/c tablets and EL also 14 f/c tablets) available. EL: 14
f/c tablets were chosen to have the identical
presentation as for O.
Indinavir Crixivan HIV infection 180 capsules 400 mg 16 Data for selected presentation available in 16 countries.
No price data available for IE (medicine not on
market).
Insulin lispro Humalog Diabetes mellitus 3-ml cartridge 100 u/ml 16 Data for selected presentation available in 16 countries.
No data available for this presentation in ES.
Lopinavir/ritonavir Kaletra HIV infection 120 tablets 200 mg/50 mg 16 Data for selected presentation available in 16 countries.
No price data available for IE (medicine not on
market).
Mycophenolate
mofetil
Cellcept Immunosuppressant 50 tablets 500 mg 17 Data for selected presentation available in 13 countries.
Data for AT, BE, CH, and DK in different pack size
(150 tablets) available and included.
continued on next page
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Mycophenolate
mofetil
Generic versions Immunosuppressant 50 tablets 500 mg 17 Data for selected presentation available in 15 countries.
Data for BE and DK in different pack size (150 tablets)
available. Data for 50 and 150 tablets available in AT
and CH; 150 tablets chosen to ensure comparability
between O and G.
Piioglitazone Actos Diabetes mellitus 28 tablets 30 mg 15 Data for selected presentations available in 17
countries. No price data available for FR (no longer
marketed) and NZ (no longer reimbursed, generic
version is reimbursed).
Pioglitazone Generic versions Diabetes mellitus 28 tablets 30 mg 6 Data for selected presentations available in 6 countries.
No price data available in 11 countries (no generics
on the market).
Prasugrel Eﬁent Prophylaxis of thrombotic
events, antiplatelet
28 tablets 10 mg 17 Data for selected presentation available in 16 countries.
Data for FR in similar pack size (30 capsules)
available.
Sunitinib Sutent Renal cell carcinoma,
gastrointestinal
stromal tumors
28/30 capsules 12.5 mg 17 Data for selected presentation available in 17 countries,
either 28 or 30 capsules.
Venlafaxine Efexor XR Depression, anxiety,
antidepressant
28/30 prolonged-release
capsules 75 mg
16 Data for selected presentation available in 13 countries.
Data for DE (50 prolonged-release capsules retard),
DK (98 prolonged-release capsules), and IT (14
prolonged-release capsules) available in different
pack size and included. No data on prolonged-
release capsules in SE available.
Venlafaxine Generic versions Depression, anxiety,
antidepressant
28/30 prolonged- released
capsules 75 mg
17 Data for selected presentations available in 15
countries. Data for DE (50 prolonged-release capsules
retard) and IT (14 prolonged-release capsules) in
different pack size available.
AT, Austria; BE, Belgium; CH, Switzerland; DE, Germany; DK, Denmark; EL, Greece; ES, Spain; f/c, ﬁlm coated; FR, France; FI, Finland; IE, Ireland; IT, Italy; NL, The Netherlands; NO, Norway; NZ,
New Zealand; PT, Portugal; SE, Sweden; UK, the United Kingdom (England, Wales).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 8 4 – 4 9 2488keep the generics included but did an additional analysis for
originator medicines only.
Sourcing European and New Zealand Price Data
The national price data from 16 European countries were pro-
vided by the Pharmaceutical Price Information (PPI) service by
Gesundheit Österreich GmbH/Austrian Health Institute [41]. The
PPI service offers, at request, medicine prices of the EU member
states covering all price types. It was established to support,
according to the Austrian General Social Insurance Law [42], the
Austrian Pricing Committee, which calculates the EU average
price. This is required for price setting because Austria applies
external price referencing and sets its prices on the basis of the
average of the prices in all other EU member states. Price data
were given for all presentations (different pharmaceutical forms,
dosages, and pack sizes) of the originator brands and the “most
common” generic medicines. Prices were given at all price types;
the ex-factory price, pharmacy purchasing price, pharmacy retail
price net, and pharmacy retail price gross (including value-added
tax) if applicable (for hospital medicines, only the ex-factory price
was indicated because no distribution margins were applied).
Price data were ofﬁcial ones; that is, they did not consider any
(conﬁdential) discounts and rebates. Prices were displayed per
unit (e.g., per tablet, vial) in national currency from June 2012.
The price data from the European countries did not always
include information whether these medicines were reimbursed
by the government funding authorities or not; however, it is most
likely that most of them are reimbursed (information provided by
PPI data providers).
New Zealand price data at ex-factory price level for funded
medicines were sourced from the New Zealand August 2012
Pharmaceutical Schedule [15].146%
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Fig. 1 – Price differences between highest- and lowest-priced m
plus a comparable generic version for 5 medicines). Information
of a medicine in the country with the highest price and the pric
indicated in percentage on the basis of the lowest-priced medicin
only the originator version is available.Data Management and Analysis
For each of the 14 medicines, the price (if indicated different than
the euro) was converted to euro for international comparison. For
price conversions, the monthly average exchange rate as of June
2012 as indicated by the European Central Bank was used [28].
Unit prices were compared at the ex-factory price level for
medicines of comparable presentations because this price type
had data available for almost all the 17 countries and because for
medicines in hospital only this price type is available (Table 1).
Data analysis was carried out using Microsoft Ofﬁce Excel 2007
and in R 2.15.2.Results
Data for the 16 European countries and New Zealand showed a
high variation in medicine prices. For most of the selected
medicines, the price of the product in the highest-priced country
was at least twice the price of the medicine in the country with
the lowest price. For a few medicines, particularly generics, the
cross-country price differences amounted up to 1000% and more
(Fig. 1; see Appendix 1 in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2015.01.003).
Among the European countries, Greece and Portugal, and also,
but to a lesser extent, Spain, United Kingdom, and The Nether-
lands frequently ranked in the lowest quartile (ﬁrst quartile), and
have displayed the lowest price in some cases. Countries ranking
at the higher end (highest quartile, i.e., fourth quartile) were
Switzerland and Germany and also Denmark and Sweden (Fig. 2;
see Appendix 2 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2015.01.003). The data for New Zealand showed
higher variability: within the 17 countries surveyed, New514%
1025%
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edicine. A total of 19 presentations (14 on-patent medicines
on data availability (cf. Table 1). Difference between the price
e of the medicine in the country with the lowest price is
e. G, generic version; O, originator medicine; if not indicated,
Country 1  quartile 2  quartile 3  quartile 4  quartile
AT 2 7 7 1
BE 5 7 4 1
CH 0 0 1 15
DE 0 1 3 13
DK 3 1 3 9
EL 13 2 3 0
ES 8 6 1 1
ES
FI
FR
IE
IT
NL
NO
NZ
PT
SE
UK
FI 5 4 6 3
FR 3 6 6 0
IE 0 3 5 6
IT 5 6 4 0
NL 7 6 5 0
NO 2 7 5 3
NZ 5 3 1 7
PT 10 4 3 0
SE 2 0 5 9
UK 8 5 4 1
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
AT
BE
CH
DE
DK
EL
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Fig. 2 – Medicine prices per quartile. Note. (left) absolute data, (right) %. AT, Austria; BE, Belgium; CH, Switzerland; DE,
Germany; DK, Denmark; EL, Greece; ES, Spain; FR, France; FI, Finland; IE, Ireland; IT, Italy; NL, The Netherlands; NO, Norway;
NZ, New Zealand; PT, Portugal; SE, Sweden; UK, the United Kingdom (England, Wales).
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 8 4 – 4 9 2 489Zealand’s prices were in the lowest quartile in ﬁve cases and
ranked lowest in four cases (abacavir, escitalopram generic
version, mycophenolate mofetil orginator version, and pioglita-
zone generic version), whereas they were in the highest quartile
in seven cases, thereof ranking highest in one case (prasugel).
The six other medicines in the highest quartile in New Zealand
were darunavir ethanolate, indinavir, insulin lipro, sunitinib, and
venlafaxine, the latter being both the originator and the com-
parable generic version.
Table 2, Figure 2, and Figure 3 highlight the differences
between New Zealand and European prices. In the four cases in
which New Zealand ranks lowest, the New Zealand prices are 6%
(mycophenolate mofetil originator), 15% (abacavir), 32% (pioglita-
zone generic version), and 65% (escitalopram generic version)
lower than that of the lowest-priced medicine in the European
countries. For prasugel (highest price in New Zealand), the New
Zealand price is 25% higher than that of the highest-priced
medicine in the European countries.
With regard to price differences between the originator and its
comparable generic version, there is again variation between the
countries, ranging from no price differences between the origi-
nator and the generic version (observed in Spain, for instance) to
generics with prices up to 90% lower than those of the originator
(e.g., in The Netherlands and the United Kingdom for some
medicines; see Appendix 3 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.01.003).Discussion
The study offered, for the ﬁrst time, a price comparison of
European and New Zealand medicine prices. It showed price
variation between the European countries and between New
Zealand and European countries.
Our ﬁndings showed that medicine prices in Greece, Portugal,
and Spain, and also the United Kingdom and The Netherlands,
ranked at the lower end, whereas prices in Switzerland, Germany,
Denmark, and Sweden were at the higher end. The results were
more or less in line with the previous price comparisons among
European countries, particularly with studies of more recent
times [8,9,23,26–31,33,34,38,43–45]. The major difference in the
literature concerns Norway, which was found to have a ratherlow price level in a study by Brekke et al. [28], but not in our
survey. It is important to consider more updated studies because
there might have been changes over time. In studies of more than
a decade ago, medicine prices in the United Kingdom, for
instance, ranked high or middle-high, but in recent publications,
including our survey, they ranked low or middle-low. Some
European countries (Greece, Portugal, Spain, and Ireland) were
hit hard by the global ﬁnancial crisis, and they had to undertake
“austerity measures” in pharmaceutical policy also. Medicine
price cuts were frequently implemented in these countries
[23,40,46], and they can explain the persisting low prices in the
Mediterranean “crisis countries” that already had a low price
level before the crisis as well as the move to the upper-middle
price level in Ireland, previously a high-price country [8].
There is no pattern regarding the high variability in price
differences between New Zealand and the European countries. In
our sample, New Zealand price data frequently ranked either in the
ﬁrst quartile or in the highest quartile. Medicines that displayed
lower prices were, in most cases, medicines for which a generic
alternative existed. These ﬁndings point to New Zealand being
successful in bringing prices for generics down to a lower level.
We acknowledge, however, that our survey focused on on-
patent medicines, and a comparison of originator and generic
medicine prices was not the focus of this price survey given
limited availability of generic medicine prices (generics were not
on the market in several countries, and in New Zealand only the
generic versions and not the originator were included in the
reimbursement list in three cases). Nonetheless, even for the few
data available, some kind of pattern could be observed. Price
differences between the highest- and the lowest-priced products
across the countries were considerably higher for generics than
for the other medicines of the sample (Fig. 1; see Appendix 1 in
Supplemental Materials). Overall, originator versions of medi-
cines with generics available tended to show higher price differ-
ences than did on-patent medicines without generic versions.
Although these data are not representative, they are in line with
other studies [35–37], which concluded that countries such as the
United Kingdom, Denmark, and Sweden, which had generic
competition work, apparently succeeded in bringing generic
medicine prices down. These countries, however, also apply
further policy options to increase generic uptake, such as man-
datory generic substitution (Sweden), highly encouraged
Table 2 – European vs NZ prices.
Medicine 16 European countries NZ
Minimum Median Average Maximum NZ price Rank*
Abacavir 2.92 4.33 4.37 6.10 2.48 1
Adefovir dipivoxil 10.74 15.98 15.40 20.20 14.04 7
Aripiprazole 2.66 3.65 3.74 5.25 2.68 3
Cyclosporine O 1.70 3.15 3.09 4.66 3.08 12
Cyclosporine G 0.76 2.07 2.04 3.10 – –
Darunavir ethanolate 8.08 10.89 10.89 14.99 12.88 16
Escitalopram O 0.53 0.60 0.70 1.41 – –
Escitalopram G 0.28 0.50 0.47 0.60 0.10 1
Indinavir 0.94 1.55 1.47 1.93 1.88 15
Insulin lispro 5.01 6.15 6.43 9.16 7.73 14
Lopinavir/ritonavir 2.58 3.59 3.78 5.61 3.98 12
Mycophenolate mofetil O 0.97 1.82 1.87 2.98 0.91 1
Mycophenolate mofetil G 0.16 0.91 0.90 1.85 0.78 6
Pioglitazone O 0.74 1.30 1.27 1.78 – –
Pioglitazone G 0.08 0.61 0.55 0.77 0.06 1
Prasugrel 1.43 1.65 1.74 2.22 2.78 17
Sunitinib 30.43 42.94 42.64 59.01 53.73 16
Venlafaxine O 0.20 0.42 0.54 1.48 0.73 13
Venlafaxine G 0.05 0.22 0.25 0.67 0.44 15
Note. NZ prices compared with the price range (minimum and maximum value), median, and average value of European prices. Ex-factory unit
prices in euro for 19 presentations (14 on-patent medicines plus a comparable generic version of 5 medicines). Information on data availability
(cf. Table 1).
G, generic version; NZ, New Zealand; O, originator medicine, if no O or G is indicated, only the originator version is available.
* Rank of the NZ price among the 17 countries of the survey (1 ¼ lowest price, 17 ¼ highest price).
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 8 4 – 4 9 2490prescribing by International Non-Proprietary Name (the United
Kingdom), and therapeutic reference pricing (Denmark and Swe-
den), which are likely to have contributed to higher generic
market shares in the countries. According to Dylst and SimoensFig. 3 – European versus New Zealand prices. New Zealand pric
value) and median value of the European prices. Ex-factory unit
plus a comparable generic version to 5 on-patent medicines). Ad
displayed in the graph for readability reason (cf. Table 2 for dat
Table 1). G, generic version; O, originator medicine; if neither O no
The bar shows the minimum-maximum range of the prices of t
European data is indicated; right to the bar (highlighted in blue)[37], there appears to be a negative relationship between generic
market shares and generic prices.
Medicine prices in a country are the result of several pricing
policies and reimbursement strategies [29]. Most Europeanes compared with the price range (minimum and maximum
prices in euro for 16 presentations (11 on-patent medicines
efovir dipivoxil, darunavir ethanolate, and sunitinib are not
a). Information on data availability and methodology (cf.
r G is indicated, only the originator version is available. Note.
he European countries. Left to the bar, the median of the
, the New Zealand price is indicated.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 8 4 – 4 9 2 491countries and New Zealand regulate the prices of reimbursable
medicines, that is, those medicines that are funded, at least
partially, by the state, whereas manufacturers can freely set the
prices of nonreimbursable medicines, which are often nonpre-
scription medicines (over-the-counter medicines) [19,36,46]. It
was not in the scope of our study to assess as to whether speciﬁc
pricing policies, that is, external price referencing versus value-
based pricing, were more successful in driving prices down. The
issue of who pays, however, is an important one from a public
health perspective. All medicines of the sample were so-called
funded medicines in New Zealand, and most medicines were
included in the outpatient reimbursement lists in the European
countries. In hospital care, medicines in Europe and in New
Zealand (if listed on the Hospital Medicines List) are always 100%
covered by the state. Being included into reimbursement does not
always correspond to funding to the full extent. In Austria, some
regions in Italy, New Zealand, and the United Kingdom, a
prescription fee is applied, and in Ireland patients are required to
pay a deductible, that is, an initial out-of-pocket expense up to a
ﬁxed amount. The most common outpatient co-payment, which
applies to all European countries of the sample except Austria,
Ireland, Italy, The Netherlands, and the United Kingdom, is a so-
called percentage co-payment for several medicines deﬁned as
“reimbursable,” which results in a sharing of the price between the
public payer and the patient [19,36,46]. In European countries, the
increase in co-payments was one of the most common cost-
containment instruments during the last years, undertaken in
response to the global ﬁnancial crisis [23,40,46]. Co-payments risk
that patients of lower socioeconomic groups refrain from purchas-
ing medicines, or ﬁlling prescriptions, with possibly negative
implications related to morbidity and mortality and, eventually,
added public health care costs [47,48]. A study assessing the
possible impact of the global ﬁnancial crisis in Greece suggested
that vulnerable groups have refrained from demanding health care
services (medicines were not particularly studied) [49]. In New
Zealand, there was concern that the increased cost to consumers
(from NZ $3/around €1.8 an item in 2012 to NZ $5/around €3.10 per
item in January 2013, with a maximum of 20 items per family per
year [50]) could have an impact on the proportion of low- to
middle-income earners able to access essential medicines [51].
Our study has some limitations. It is based on single medi-
cines, and therefore our ﬁndings can only provide an indication
for the price level of medicines in a country. The basket of
medicines is not very large, but it includes a range of medicines
addressing different indications. The rather small size of the
basket resulted from limited data availability and comparability
between European countries and New Zealand, since we previ-
ously started with a list of 43 medicines for which we had
European price data, but then reduced the number given limited
comparable products with price information in New Zealand.
The price survey is based on ofﬁcial list prices. We are aware
that in many European countries and in New Zealand actual
prices are different (i.e., lower) because discounts and rebates, in
different forms (e.g., price-volume agreements and risk-sharing
schemes), are granted by industry to public payers [52]. Because
these discounts and rebates are mostly conﬁdential and not
disclosed, they were not included in the price data we received.Conclusions
Medicine prices varied considerably between European countries
and New Zealand. Within the European countries, Greece, Portu-
gal, the United Kingdom, and Spain had prices at the lower end,
whereas prices in Switzerland, Germany, Denmark, and Sweden
were at the upper end. These differences are likely attributable to
underlying national pricing and reimbursement policies, whichare affected by public health and industry-related policy goals as
well as by the economic situation of the country. The study
conﬁrmed that countries that were strongly hit by the global
ﬁnancial crisis took several cost-containment measures related
to medicine prices such as price cuts. Although the study focus
was not on generics, research still provided some indication that
generic policies apparently have an impact on the availability and
prices of the generics.Acknowledgments
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